Genetically associated CD16 +56 - natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline

Journal of Infectious Diseases

Volumn 205, Issue 7, 2012, Pages 1131-1141

  Conry, Sara J ^a   Meng, Qinglai ^a   Hardy, Gareth ^a   Yonkers, Nicole L ^a   Sugalski, Julia M ^a   Hirsch, Amy ^a   Davitkov, Perica ^a   Compan, Anita ^a   Falck Ytter, Yngve ^a   Blanton, Ronald E ^b   Rodriguez, Benigno ^b   Harding, Clifford V ^a   Anthony, Donald D ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ASPARTATE AMINOTRANSFERASE; CD16 ANTIGEN; CD56 ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PEGINTERFERON ALPHA2A; RIBAVIRIN; STAT1 PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG WITHDRAWAL; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERLEUKIN 28B GENE; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS INHIBITION;

ADULT; AGED; ANTIGENS, CD56; ANTIVIRAL AGENTS; FEMALE; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84858208586     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis027     Document Type: Article

References (39)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52. (Pubitemid 32634271)
2. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34:809-16. (Pubitemid 32928008)
3. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-9. e18.
4. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-48. (Pubitemid 39628231)
5. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9. (Pubitemid 38988594)
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50. (Pubitemid 38988593)
8. O'Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet 2009; 41:1048-50.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
10. Habu S, Akamatsu K, Tamaoki N, Okumura K. In vivo significance of NK cell on resistance against virus (HSV-1) infections in mice. J Immunol 1984; 133:2743-7. (Pubitemid 15206935)
11. McIntyre KW, Welsh RM. Accumulation of natural killer and cytotoxic T large granular lymphocytes in the liver during virus infection. J Exp Med 1986; 164:1667-81. (Pubitemid 17184196)
12. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells [see comments]. N Engl J Med 1989; 320:1731-5. (Pubitemid 19163129)
13. Cauda R, Laghi V, Tumbarello M, Ortona L, Whitley RJ. Immunological alterations associated with recurrent herpes simplex genitalis. Clin Immunol Immunopathol 1989; 51:294-302. (Pubitemid 19116588)
14. Goodyear HM, McLeish P, Randall S, et al. Immunological studies of herpes simplex virus infection in children with atopic eczema. Br J Dermatol 1996; 134:85-93. (Pubitemid 26030997)
15. Joncas J, Monczak Y, Ghibu F, et al. Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J Med Virol 1989; 28:110-7. (Pubitemid 19189044)
16. Lanier LL, Spits H, Phillips JH. The developmental relationship between NK cells and T cells. Immunol Today 1992; 13:392-5.
17. Moretta L, Ciccone E, Poggi A, Mingari MC, Moretta A. Ontogeny, specific functions and receptors of human natural killer cells. Immunol Lett 1994; 40:83-8. (Pubitemid 24175032)
18. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-4. (Pubitemid 39038423)
19. Vidal-Castineira JR, Lopez-Vazquez A, Diaz-Pena R, et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 2010; 84:475-81.
20. Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141:1231-9.
21. Bozzano F, Picciotto A, Costa P, et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol 2011; 41:2905-14.
22. Stegmann KA, Bjorkstrom NK, Veber H, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138:1885-97.
23. Conry SJ, Milkovich KA, Yonkers NL, et al. Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. J Virol 2009; 83:11175-87.
24. Snyder N, Gajula L, Xiao SY, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006; 40:535-42. (Pubitemid 44318139)
25. Liang H, Russell RS, Yonkers NL, et al. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol 2009; 83:15.
26. Ogbomo H, Hahn A, Geiler J, Michaelis M, Doerr HW, Cinatl J Jr. NK sensitivity of neuroblastoma cells determined by a highly sensitive coupled luminescent method. Biochem Biophys Res Commun 2006; 339:375-9. (Pubitemid 41697560)
27. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 2007; 581:1317-22. (Pubitemid 46452605)
28. Dahari H, Affonso de Araujo ES, Haagmans BL, et al. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol 2010; 53:460-7.
29. Gonzalez VD, Falconer K, Bjorkstrom NK, et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009; 183:6612-8.
30. Bozzano F, Costa P, Passalacqua G, et al. Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. Int Immunol 2009; 21:779-91.
31. Morishima C, Paschal DM, Wang CC, et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 2006; 43:573-80.
32. Parra EJ, Marcini A, Akey J, et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998; 63:1839-51. (Pubitemid 30415746)
33. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139:1865-76.
34. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4.
35. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9.
36. Wapner J. Pharmacogenomics. Gene variants affect hepatitis C treatment, but link is elusive. Science 2010; 330:579.
37. Witte K, Gruetz G, Volk HD, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10:702-14.
38. Gonzalez VD, Falconer K, Michaelsson J, et al. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 2008; 128:46-56.
39. Miyagi T, Takehara T, Nishio K, et al. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010; 53:424-30.